logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

Is there still light at the end of the tunnel for priority schools?

14 May 2013

The Government has announced that 137 of the 221 schools on its Priority School Building Programme (PSBP) will now be delivered using capital funding after failing to raise sufficient private capital.

Whilst the Government has confirmed the first batch of schools will go out to the market in June – to be followed in the next 12 months by a further four batches – the value of the privately financed element of the PSBP has been slashed by almost £1bn to £700m.

This is a major blow both to the Government’s plans to pilot their new private finance approach PF2 on the PSBP and to those schools in dire need of rebuilding, many of whom were victims of the government’s cull of the Building Schools for the Future (BSF) programme in 2010.

One hopes swift progress is made on the first and subsequent batches of privately financed schemes. Only then might the dying embers of the flickering light at the end of the tunnel be rekindled!

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up